Bayer AG
362 articles with Bayer AG
-
Bayer Acquires Asklepios BioPharmaceutical to Broaden Innovation Base in Cell and Gene Therapy
10/26/2020
Acquisition fuels Bayer’s cell and gene therapy platform with potential to bring urgently needed treatments to patients across multiple disease areas with high unmet need
-
Leaps by Bayer Leads USD 17 Million Series B Financing in Biotech Company Azitra
10/15/2020
Harnessing the human skin microbiome to develop cutting-edge solutions moving the paradigm from treatment to cure in dermatology
-
Vincera Pharma, Inc Announces Exclusive License Agreement for Oncology Portfolio Including a Clinical-stage PTEFb/CDK9 Inhibitor and a Preclinical Bioconjugation Platform
10/8/2020
P ortfolio includes VIP152, a highly selective PTEFb /CDK9 inhibitor with encouraging Phase 1 monotherapy activity , including complete responses in DH-DLBCL Vincera intends to pursue multiple accelerated approval opportunities in M YC - and MCL1- driven cancers Preclinical bioconjugation platform designed to overcome limitations of small - molecule and antibody - drug conjugates use to treat cancer SANTA CLARA, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE)
-
Bayer and Northpond Ventures Lead USD 55 million Series A Financing Round for Triumvira Immunologics
8/27/2020
Leaps by Bayer and Northpond Ventures co-lead the investment to support development of next-generation immuno oncology treatments
-
Bayer and Temasek Unveil Innovative New Company Focused on Developing Breakthroughs in Vertical Farming
8/12/2020
Called Unfold, the new company will be headquartered in the Davis, Calif., area with key operations in both the U.S. and Singapore
-
Bayer AG Standardizes on Veeva Vault Clinical Applications Globally
7/23/2020
Global life sciences leader selects Vault Study Startup and Vault eTMF to improve trial efficiency
-
Investigational Drug Vericiguat Significantly Reduced the Risk of the Composite Endpoint of Heart Failure Hospitalization or Cardiovascular Death, Compared to Placebo, When Given in Combination with Available Heart Failure Therapies
3/28/2020
Phase 3 VICTORIA Trial is the First Contemporary Outcomes Study Focused Exclusively on a Chronic Heart Failure Patient Population Following a Worsening Event
-
Elanco Signs Agreement with Vetoquinol to Divest Rights for Drontal® and Profender® Within the European Economic Area and the United Kingdom
2/12/2020
Elanco Animal Health Incorporated announced it has signed an agreement to divest the European Economic Area and UK rights to the Drontal® and Profender® product families from Bayer AG’s animal health business, to Vetoquinol SA, a French pharmaceutical company, for $140 million in an all-cash deal subject to customary post-closing adjustments.
-
Evotec And Bayer Advance Further Programme Into Phase I Clinical Development
1/30/2020
Evotec SE announced that its partner Bayer AG has decided to advance a further programme from the endometriosis multi-target alliance into clinical Phase I development.
-
Elanco Animal Health Announces Common Stock and Tangible Equity Unit Offerings Associated with Financing Acquisition of Bayer’s Animal Health Business
1/21/2020
Elanco Animal Health Incorporated announced it intends to make concurrent public offerings of 19,159,866 shares of its common stock and 11,000,000 tangible equity units, with an aggregate stated amount of $550 million for the units.
-
Bayer AG and Monsanto Look to Minimize Losses from Cancer Victims' Exposure to Roundup
1/11/2020
Bayer AG and its Monsanto subsidiary are hoping to minimize losses at the expense of nearly 43,000 cancer victims who have filed suit after falling ill following exposure to the popular weed killer Roundup.
-
Evotec and Bayer Announce New Alliance Focusing on Drug Discovery for Polycystic Ovary Syndrome With Novel Targets From Celmatix
1/9/2020
New five-year, multi-target alliance aims to translate first-in-class science and drug discovery into new drugs for polycystic ovary syndrome
-
Bayer and Exscientia collaborate to leverage the potential of artificial intelligence in cardiovascular and oncology drug discovery
1/9/2020
Exscientia, the leading Artificial Intelligence -driven drug discovery company, announced today that it has entered a collaboration with Bayer AG that aims to accelerate the discovery of small molecule drugs focused on cardiovascular disease and oncology.
-
Simulations Plus Partners with Bayer AG to Develop New Cheminformatics Capabilities in ADMET Predictor
12/5/2019
New Structure and Tautomer Handling Routines Aim to Improve Data Integrity in Drug Discovery
-
ProBioGen Licenses GlymaxX® Technology to Bayer
9/10/2019
ProBioGen AG announced the closing of a license agreement with Bayer AG for the GlymaxX® Technology.
-
Versant Ventures Announces Acquisition of Cell Therapy Company BlueRock Therapeutics
8/8/2019
Another successful outcome from a Versant-created company in a breakthrough field
-
Bayer acquires BlueRock Therapeutics to build leading position in cell therapy
8/8/2019
Bayer AG and BlueRock Therapeutics announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary induced pluripotent stem cell platform.
-
Parasitic Diseases Therapeutics Market Worth USD 1.79 Billion, at 5% CAGR During 2019-2023 | Technavio
6/19/2019
According to Technavio Research Report "Parasitic Diseases Therapeutics Market by type and geographic regions is witnessed to grow USD 1.79 billion, at a CAGR of 5% from 2019 to 2023”.
-
Bayer and Foundation Medicine announce global collaboration to develop next-generation sequencing (NGS)-based companion diagnostics in oncology
5/29/2019
Bayer AG and Foundation Medicine, Inc. announced a global collaboration for the development and commercialization of NGS-based companion diagnostics.
-
The first project the companies aim to develop is a companion diagnostic for Vitrakvi, the only TRK inhibitor approved in the U.S. for patients with TRK fusion cancer across all solid tumors.